Biocon Ltd
BION.NS- Latest Trade
- trading lower311.15INR
- Change
- -4.6
- % Change
1.46%Negative
- As of Aug 15 2022. Values delayed up to 15 minutes
- Day Range
- 310.55 - 315.60
- 52-Week Range
- 305.00 - 410.70
- Previous Close
- 315.75
- Open
- 314.00
- Volume
- 1,477,133.00
- 3 Month Average Trading Volume
- 44.52
- Shares Out (Mil)
- 1,191.81
- Market Cap
- 370,830.30
- Forward P/E
- 31.58
- Dividend Yield
- 0.16
Key Statistics
2.28571429 mean rating - 21 analysts
- P/E Excl. Extra Items (TTM)
- 52.59
- Price To Sales (TTM)
- 4.33
- Price To Book (Quarterly)
- -99,999.99
- Price To Cash Flow (Per Share TTM)
- 22.24
- Total Debt/Total Equity (Quarterly)
- -99,999.99
- Long Term Debt/Equity (Quarterly)
- -99,999.99
- Return On Investment (TTM)
- -99,999.99
- Return On Equity (TTM)
- -99,999.99
2021 (millions USD)
About Biocon Ltd (BION.NS)
Company Information
Biocon Limited is an India-based biopharmaceutical company that focuses to treat diabetes, cancer and autoimmune diseases. The Company is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
Address
20th KM, Hosur Road, Electronics CityBANGALORE,
560100
India
Industry
Biotechnology & Drugs
Executive Leadership
- Kiran Mazumdarshaw
- Executive Chairperson of the Board
- Siddharth Mittal
- Chief Executive Officer, Managing Director, Executive Director
- Indranil Sen
- Chief Financial Officer
- Shreehas P. Tambe
- Deputy Chief Executive Officer
- Amitava Saha
- Chief Human Resource Officer
- Mayank Verma
- Compliance Officer, Company Secretary
- Sriram A.V.
- Head - Quality
- Seema Ahuja
- Chief Communications Officer
- Prasad Deshpand
- Head - Supply Chain and Central Engineering
- Vijaya S. Kumar
- Head - Operations
- Manoj Kumar Pananchukunnath
- Head - Research and Development and Regulatory Sciences
- Paul Vazhayil Thomas
- Chief Commercial Officer, US and Portfolio Strategy and Business Development, Advanced markets
- Nehal Vora
- Commercial Head - Biocon Global APIs
- Abhijit Zutshi
- Commercial Head - Biocon Global Generics
- Eric Vivek Mazumdar
- Non-Executive Non-Independent Director
- Ravi Rasendra Mazumdar
- Non-Executive Non-Independent Director
- Meleveetil Damodaran
- Lead Non-Executive Independent Director
- Naina Lal Kidwai
- Additional Non-Executive Independent Director
- Vijay Kumar Kuchroo
- Non-Executive Independent Director
- Bobby Kanubhai Parikh
- Non-Executive Independent Director
Latest News
- MarketsDeals of the day Mergers and acquisitions
The following bids, mergers, acquisitions and disposals were reported by 2045 GMT on Monday:
- MarketsIndia's Biocon beefs up biosimilar portfolio with $3.34 bln Viatris deal, shares fall
Shares of Indian drugmaker Biocon Ltd fell about 12% on Monday after the company said its unit Biocon Biologics would buy U.S.-based Viatris Inc's biosimilars business in a transaction valued at $3.34 billion.
- MarketsIndia's Biocon in talks with Mylan to merge biosimilar businesses - Moneycontrol
Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website Moneycontrol reported on Thursday, citing sources with direct knowledge of the matter.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,777.10 | 0.24%Negative |
| Copper | 668.75 | 1.08%Negative |
| Brent Crude Oil | 94.23 | 0.91%Negative |
| CBOT Soybeans | 1,489.00 | 0.33%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,297.14 | 0.40%Positive |
| Euro STOXX 50 | 3,789.62 | -- |
| FTSE 100 | 7,509.15 | 0.11%Positive |
| Nikkei 225 | 28,850.41 | 0.07%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes